抗体偶联药物和小分子偶联药物的研究进展

Research and Development of Antibody-drug Conjugates and Small Molecule-drug Conjugates

细胞毒分子的靶向治疗解决了传统化疗药物不能专一靶向肿瘤细胞、引起正常组织毒性的难题。抗体偶联药物和小分子偶联药物能够选择性地将细胞毒分子递送并作用于肿瘤细胞上,减轻了不良反应,是肿瘤靶向治疗的重要策略之一。本文阐述了抗体偶联药物和小分子偶联药物的设计原则并简单介绍了二者的发展状况。

The development of targeted cytotoxics represents an area of pharmaceutical research in constant evolution.Targeted therapy of cytotoxic molecules has solved the problems that conventional chemotherapeutics cannot specifically localize at the tumor site and cause toxicity to normal tissue.Antibody-drug conjugates(ADCs)and small molecule-drug conjugates(SMDCs)that have great advantages over traditional non-targeted therapeutic agents can selectively deliver cytotoxic molecules to tumor cells and reduce side effects,which are important strategies of tumor targeted therapy.This review aims to cover design principles of ADCs and SMDCs and provide an overview of the developments of ADCs and SMDCs.